Mesenchymal stem cell therapy for bronchopulmonary dysplasia and haemorrhage - Medipost

Alternative Names: Pneumostem

Latest Information Update: 04 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Medipost
Developer Medipost; Samsung Medical Center
Class Antineoplastics; Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Bronchopulmonary dysplasia
New Molecular Entity No
Available For Licensing Yes - Bronchopulmonary dysplasia

Highest Development Phases

Phase II Bronchopulmonary dysplasia; Haemorrhage

Most Recent Events

08 Jan 2018 Medipost plans a phase II trial for Bronchopulmonary Dysplasia (In infants) in South Korea in January 2019 , (NCT03392467)
04 Nov 2017 No recent reports of development identified for phase-I development in Haemorrhage(In infants) in South Korea
28 Mar 2017 Phase-II clinical trials in Haemorrhage (In neonates) in South Korea (unspecified route) (NCT02890953)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.